In initial attempts to gain antiproliferative mechanistic insights, we conducted cell cycle perturbation studies with a variety of aggressive human cancer cell lines as follows: colon cancer p53 positive HCT116p53+/+ and p53 negative HCT116p53−/− cells, non-small cell lung cancer A549 cells, prostate cancer LNCaP, DU145 and PC3 cells; and to test cancer cell selectivity, we also tested the effects of selected compounds on the cell cycle of normal human fibroblast cells. This evidence concerns the gene TP53 and non-small cell lung carcinoma.